Log in
Enquire now
‌

ImmPORT Therapeutics Inc dba Antigen Discovery Inc SBIR Phase I Award, August 2018

A SBIR Phase I contract was awarded to ImmPORT Therapeutics Inc dba Antigen Discovery Inc in August, 2018 for $225,707.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1565543
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
ImmPORT Therapeutics Inc dba Antigen Discovery Inc
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R43AI136196-010
Award Phase
Phase I0
Award Amount (USD)
225,7070
Date Awarded
August 16, 2018
0
End Date
July 31, 2019
0
Abstract

PanHIV Incidence Assay DevelopmentAbstractHIVcontinues to cause the largest number of yearly deaths from a single infectious agent in the world todayDespiteconsiderableadvancesintreatmentofHIVinfectionandAIDSwhichitcausesthereisanurgentneed for better methods of prevention and treatment of HIVinfection and AIDSAs part of this effortthe WorldHealth OrganizationWHOand the Joint United Nations Program on HIV AIDSUNAIDSconduct worldwidesurveys of HIV infection incidenceprevalence and mortalityIncidence data are vitally needed by governmentsandnongovernmentalorganizationstobestdirecteffortsandlimitedresourcesaimedatpreventionofHIVtransmission and treatment of HIV infectionThe limiting antigen avidity enzyme immunoassayLag assayiscurrently widely used to test for HIV incidence but this assay only detects very recent infections and does notwork well for all subtypes of HIVAntigen Discovery IncADIof Irvine Californiahas created a panHIV proteomic microarraypanHIV chipthatcontainsallproteinsandmanyproteinfragmentsandepitopesfromnineHIVsubtypesandcirculatingrecombinant forms as well as both major groups of HIVwhich together comprise overof HIV infectionsworldwideWealsoaddedglycosylatedanddisulfideboundformsofHIVglycoproteinsandglycoproteinfragmentsresultinginatotalofoverimmunoreactiveHIVproteinsproteinsfragmentsandepitopesMoreoverwe assayed the reactivity of this HIV protein microarray with IgGIgA and IgM in a panel ofseraand saliva samplesobtained from the Consortium for the Evaluation and Performance of HIV Incidence AssaysCEPHIAthatcomprisetheHIVRecencyBiomarkerScreeningHRBSsetOurpreliminarydatashowthatcertain HIV antigensVifVpupTatRevEnv and Env fragments are much less strongly recognized by IgGin sera and saliva from recently infected individuals compared to those with longerterm infectionIn contrastEnvEnv fragmentsTatRevCA and PR are more strongly recognized by IgM in sera and saliva from recentlyinfected individuals compared to those with longerterm infectionBased on these extensive preliminary datawehypothesizethatwecandevelopahighlysensitiveandspecificHIVrecencyofinfectiontestingalgorithmRITAthat will be useful for individuals infected with all types and subtypes of HIVPanHIV Incidence Assay DevelopmentAbstractHIVcontinues to cause the largest number of yearly deaths from a single infectious agent in the world todayDataonhowmanynewinfectionsoccuryearlyarevitallyneededtobestdirecteffortsandlimitedresourcesaimed at prevention of HIV transmission and treatment of HIV infectionThe current test for new HIV infectionsis not optimalwe plan to develop a more comprehensive and specific test of recent HIV infection

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like ImmPORT Therapeutics Inc dba Antigen Discovery Inc SBIR Phase I Award, August 2018

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.